Papers

1

Total Citations

19

H-Index

1

About

Andrew Katsifis is a leading figure in radiopharmaceutical chemistry and molecular imaging, whose work has profoundly advanced the field of positron emission tomography (PET) for neuroinflammation. His primary research focuses on the design, synthesis, and radiolabelling of novel ligands for the translocator protein (TSPO), a key biomarker for activated microglia in neurodegenerative diseases. Katsifis’s most notable contribution is the development of [¹⁸F]PBR111, a high-affinity and selective radioligand for TSPO. His seminal 2008 paper on the automated radiosynthesis of this tracer, which has garnered 19 citations, established a reliable method for producing this critical imaging agent. This work is a cornerstone for PET studies investigating conditions like Alzheimer’s disease, multiple sclerosis, and traumatic brain injury. By enabling the non-invasive visualisation of neuroinflammation, Katsifis’s research has provided a powerful tool for both basic neuroscience and clinical drug development, cementing his reputation as an innovator in the synthesis of next-generation radiopharmaceuticals.

Research Focus

Key Achievements

1
H-Index
1
Papers
19
Total Citations
19
Avg Citations/Paper
🏆 Most Cited Paper
Radiosynthesis of [<sup>18</sup>F]PBR111, a selective radioligand for imaging the translocator protein (18 kDa) with PET
19 citations · 2008
📈 Most Prolific Year: 2008 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Australian Nuclear Science and Technology Organisation

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago